Article
Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.
Bioorganic & medicinal chemistry letters - 15 Nov 2023
Lian Xuanmin, Gao Yue, Li Xuemei, Wang Peipei, Tong Lexian, Li Jia, Zhou Yubo, Liu Tao
Abstract excerpt
Acute myeloid leukemia (AML) is an aggressive cancer, which is characterized by clonal expansion of myeloid progenitors in the bone marrow and peripheral blood. FMS-like tyrosine kinase 3 (FLT3) mutations are the most frequently identified mutations, present in approximately 25-30 % AML patients, making FLT3 inhibitors a crucial treatment option for AML. In this study, we described the design, synthesis and...
Topics
- Humans
- fms-Like Tyrosine Kinase 3
- Protein Kinase Inhibitors
- Cell Line, Tumor
- Mutation
- Leukemia, Myeloid, Acute
- Apoptosis